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ABSTRACT
Introduction: Drug-induced parkinsonism
(DIP) and tardive dyskinesia (TD) are stigma-
tizing movement disorders associated with
exposure to dopamine receptor blocking agents
such as antipsychotics, but they differ in their
pathophysiology and clinical management.
Treatment for one may worsen the other, and
there are important diagnostic clues that assist
in making an accurate assessment and institut-
ing a rational treatment plan.
Methods: A literature review was executed to
identify articles relating to the presentation,
pathophysiology, epidemiology, and manage-
ment of DIP and TD.
Results: DIP and TD prevalence estimates range
from approximately 20 to 35% among antipsy-
chotic users, but may be higher in select popula-
tions. DIP often presents as bradykinesia and
rigidity, as well as rhythmic tremor, and the
majority of cases appear within hours to weeks of
initiation of therapy with an antipsychotic, or if
dosage of the antipsychotic is increased. TD onset
is delayed, typically appearing after at least
3 months or longer of treatment, and patients
will commonly present with involuntary, abnor-
mal facial movements such as lip smacking,
puckering, chewing, or tongue protrusion. DIP
often resolves with discontinuation of the causa-
tive agent, but TD may be permanent. Broadly,
proposed mechanisms underlying these adverse
events include decreased dopamine concentra-
tions in the nigrostriatal pathway of the striatum
and dopamine hypersensitivity, for DIP and TD,
respectively. Pharmacologic treatment approa-
ches for DIP have commonly included anti-
cholinergic agents such as benztropine; however,
anticholinergic medications can make TD worse.
Switching the antipsychotic medication to one
with lower propensity for DIP is an option for
some patients. Amantadine, a non-anticholiner-
gic agent used for the treatment of DIP, may be
preferred in patients with comorbid DIP and TD.
In TD, treatment options include the new rever-
sible vesicular monoamine 2 transporter inhibi-
tors, valbenazine and deutetrabenazine.
Conclusions: It is important for clinicians to be
able to recognize DIP and TD in patients using
antipsychotics so that they can minimize the
impact of these adverse events on their patients’
quality of life. Accurate diagnosis will drive the
selection of the correct treatment.
Plain Language Summary: Plain language
summary available for this article.
Enhanced digital content To view enhanced digital
content for this article go to https://doi.org/10.6084/
m9.figshare.6736412.
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Antipsychotic medications are often used to
treat serious mental illnesses, like schizophrenia
and bipolar disorder. In some people, these
medications cause uncontrollable movements
in the face and limbs. Two of the more common
movement disorders are called drug-induced
parkinsonism (DIP) and tardive dyskinesia (TD).
DIP usually starts within days to months after
starting an antipsychotic, whereas TD may
begin months to years later. The more common
signs of DIP are tremor and movements that
appear slow and stiff, and TD usually includes
face movements like lip puckering or smacking,
and chewing. These side effects are often
embarrassing for the patient, can get in the way
of their daily activities, and may be permanent.
It is important for clinicians to watch for these
side effects, and to understand the different
treatment options because most medications
used to treat DIP should not be used to treat TD.
There are no medications used regularly to
prevent TD. However, there are new medica-
tions for the treatment of TD that have signifi-
cant potential to help patients who develop
movement side effects while taking
antipsychotics.
INTRODUCTION
Movement disorders, or extrapyramidal side
effects (EPS), are potential adverse events of
antipsychotic use that are often stigmatizing,
and can impair patients’ ability to complete
activities of daily living. A study assessing
quality of life among patients with
stable schizophrenia symptoms on clozapine, or
a typical antipsychotic, found that less EPS was
predictive of better quality of life scores in both
groups [1]. Although movement disorders were
once thought of primarily as a concern associ-
ated with typical, or first-generation, antipsy-
chotic use, increasing recognition is being given
to the possibility of most atypical, or second-
generation, antipsychotics to precipitate move-
ment disorders. As atypical antipsychotic use is
highly prevalent in the treatment of serious
mental illness, it is timely to discuss clinical
approaches for treating two relatively common
antipsychotic-induced movement disorders:
drug-induced parkinsonism (DIP) and tardive
dyskinesia (TD). The aim of the following dis-
cussion is to approach the review of these
adverse events with a focus on the similarities
and differences of DIP and TD with respect to
their epidemiology, presentation, pathophysi-
ology, and management. Understanding the
differences between these two movement dis-
orders is particularly important as the treatment
approaches are distinct and rely on the accurate
identification of the underlying movement
disorder.
METHODS
On March 29, 2018, the PubMed database was
searched with the terms: antipsychotic AND
(parkinson* OR ‘‘tardive dyskinesia*’’), and the
results were examined for articles pertaining to
the epidemiology, diagnosis, pathophysiology,
and treatment of parkinsonism and tardive
dyskinesia resulting from treatment with
antipsychotics. This search was repeated on
April 19, 2018 to identify any new literature
published since the original query. Results were
notable for sparse primary literature supporting
the use of most medications (with the exception
of valbenazine and deutetrabenazine) for the
treatment of antipsychotic-induced DIP or TD.
This article reviews previously published mate-
rial, and no new information from human par-
ticipants or animal research conducted by
either of the authors was used in this article.
DRUG-INDUCED PARKINSONISM
Epidemiology
DIP is difficult to distinguish from Parkinson’s
disease, particularly in elderly patients, and is
often undiagnosed [2, 3]. These factors make it
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challenging to understand the scope of
antipsychotic-induced parkinsonism. Preva-
lence rates in studies that include patients tak-
ing typical and atypical antipsychotics range
from approximately 20 to 35% [4–6], but DIP
occurs at higher rates in elderly patients [7].
Several studies have retrospectively assessed
medications as causes of identified parkinson-
ism. In a review focused on the elderly, 46% of
those with symptoms due to medications were
deemed to be caused by atypical antipsychotics
[8]. This is contrasted by a recent report of a
30-year epidemiologic study of parkinsonism,
in which typical antipsychotics were identified
as the culprit of the majority of all drug-induced
cases, with almost no contribution from atypi-
cal antipsychotics [9]. These differences may be
due to varied populations and study design but,
ultimately, they demonstrate that DIP is still a
concern of antipsychotic therapy despite the
hope that it would abate with increased atypical
antipsychotic use.
Pathophysiology
The pathophysiology of DIP is related to drug-
induced changes in the basal ganglia motor
circuit secondary to dopaminergic receptor
blockade [2]. When dopamine D2 receptors in
the striatum are blocked, the gamma-
aminobutyric acid (GABA)- and encephalin-
containing striatal neurons are disinhibited,
impacting the indirect pathway, and ultimately
leading to a relative decrease in activity in tha-
lamocortical circuitry (see Fig. 1a) [2, 10]. This
effect can be moderated by anticholinergic
activity of the antipsychotic [11, 12], as sup-
ported by observations that clozapine, which is
associated with minimal-to-absent propensity
to cause DIP [13], also has a high relative affin-
ity for muscarinic cholinergic receptors [11].
Decreased effective dopamine concentrations in
the striatum can also be caused by decreased
dopamine release into the synapse; as can be
seen with the irreversible vesicular monoamine
transporter inhibitor, reserpine [12]. Medica-
tions whose primary mechanism does not
involve direct action on dopamine concentra-
tions (valproic acid, calcium channel blockers)
can cause DIP through unclear mechanisms
that may involve modulating GABA activity or
mitochondrial dysfunction [2, 12, 14]. A sum-
mary of the basal ganglia direct and indirect
pathways is presented in Box 1.
Presentation and Diagnosis
Relative to TD, DIP presents earlier in antipsy-
chotic treatment, with approximately 50–75%
of cases appearing within the first month, and
90% of cases within the first 3 months [15].
Table 1 highlights select differences between
DIP and TD. Acute dystonic reactions can occur
relatively soon after administration of intra-
muscular antipsychotic such as haloperidol
[16, 17]. Where tremor is evident, it is rhythmic,
occurring at a frequency of 3–6 Hz. Because DIP
can be associated with impairments of facial
expression, it is important to differentiate
between negative symptoms in patients with
schizophrenia, or the possibility of untreated
depression [18]. As mentioned previously, DIP
can be difficult to distinguish from Parkinson’s
disease. Characteristic symptoms, like bradyki-
nesia, rigidity, and instable gait are present in
both disorders, and while some studies note
different prominence of symptoms between DIP
and Parkinson’s disease (more bradykinesia,
symmetry of symptoms, and rigidity in DIP),
others suggest that these clues in presentation
are inadequate for an accurate diagnosis
[2, 12, 19, 20]. For example, abnormal move-
ment patterns present asymmetrically in a sig-
nificant minority of cases. Pieters et al. [21]
recently noted asymmetrical symptoms in as
many as 20% of patients with DIP, as was also
observed by Savica et al. [9]. Furthermore,
antipsychotic use may unmask Parkinson’s dis-
ease, which contributes the difficulty of diag-
nosing DIP in elderly patients [2].
Another difference in DIP and Parkinson’s
disease that may be useful in forming a diag-
nosis is improvement when the causative med-
ication’s dose is lowered or discontinued [22].
Finally, dopamine transporter (DAT) imaging
approaches have been shown capable of differ-
entiating DIP from Parkinson’s disease by
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comparing symmetry of radiotracer uptake in
the striatum [2, 23, 24].
Akathisia can be observed alongside DIP, or
in the absence of overt DIP. Akathisia is defined
as a syndrome with subjective symptoms often
accompanied by objective findings [25]. Sub-
jective symptoms include inner tension, anxi-
ety, irritability, discomfort, restlessness, or
sleeplessness. Objective findings that are often
present include movements that are semivoli-
tional, purposeful and suppressible, repetitive,
complex, and stereotypical. The pathophysiol-
ogy of drug-induced akathisia likely differs from
that for DIP. Both can improve with reduction
of antipsychotic dose; however, anticholinergic
medications are generally unhelpful in
managing akathisia [26]. Treatment of akathisia
includes administration of either a beta-adren-
ergic antagonist or a serotonergic 5HT2 receptor
antagonist.
Risk Factors
A number of risk factors have been associated
with DIP development, including: older age,
female gender, previous EPS caused by antipsy-
chotics, family history of PD, cognitive impair-
ment, HIV infection, and higher potency and
longer duration antipsychotic use [9, 27]. Use of
additional medications that may cause DIP
include valproic acid, gut motility agents like
Fig. 1 Changes in basal ganglia-thalamocortical motor
loop due to blockade of D2 receptors by DRBAs. The
blockage of D2 receptors by DRBAs in the striatum leads
to disinhibition of GABA- and encephalin-containing
striatal neurons at the origin of the indirect pathway,
followed by a disinhibition of the subthalamic nucleus.
This leads to increased GABAergic inhibition of the
thalamocortical projection by facilitation of the inhibitory
projection from the GPi/SNr (a). Chronic D2 receptor
blockade also induces changes in the direct pathways of the
basal ganglia-motor loop to cause orolingual dyskinesia (b).
DA dopamine, DRBAs dopamine receptor blocking agents,
GABA gamma-aminobutyric acid, GPe globus pallidus pars
externa, GPi globus pallidus pars internal, SNc substantia
nigra pars compacta, SNr substantia nigra pars reticulata,
STN subthalamic nucleus, TD tardive dyskinesia. Repro-
duced as per the terms of the Creative Commons
Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0) from [2])
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metoclopramide, antidepressants, and calcium
channel blockers like verapamil [12]. Impor-
tantly, the vesicular monoamine transporter 2
(VMAT2) inhibitor, tetrabenazine, treats TD but
also potentially contributes to DIP risk by
decreasing the amount of dopamine released
into the synapse, as observed in clinical trials for
Huntington’s disease [12]. This is potentially
not as concerning with the newer VMAT2
inhibitors, valbenazine and deutetrabenazine,
as observed in clinical trials for TD; however,
patients with comorbid neurological conditions
that could interfere with TD assessment were
excluded from these trials [28, 29]. The product
label for deutetrabenazine includes a warning
regarding Parkinsonism, but this is directed
towards persons receiving the medication for
Huntington’s disease, not TD [30].
Management
The necessary first step in managing DIP is
recognition through monitoring at an appro-
priate frequency. The American Psychiatric
Association (APA) recommends monitoring for
acute onset extrapyramidal side effects weekly
during initial treatment and until stable for
2 weeks, then at every follow-up visit [18].
Although clinical monitoring for signs and
symptoms of DIP may be adequate, a more
structured approach is the use of the Simp-
son–Angus Extrapyramidal Side Effect scale,
which is a quick 10-item measure that has
demonstrated efficacy in the early detection of
DIP [31–33], and is commonly used in clinical
trials of antipsychotic medications.
Whenever possible, discontinuation of the
causative agent is the recommended treatment
strategy for distressing DIP symptoms. Unlike in
the management of TD, where this approach
results in a transient worsening of symptoms, it
will lead to improvement of DIP symptoms
within days to months after stopping therapy.
However, DIP symptoms have been observed to
persist in 10–50% of patients [2]. It is often not
possible to discontinue antipsychotics, but the
use of any additional agents potentially con-
tributing to DIP risk should be carefully recon-
sidered. If reasonable in the course of the
patient’s treatment, it is appropriate to consider
switching to an antipsychotic with less
propensity to cause DIP, such as from a typical
to an atypical agent. Quetiapine is often an
agent of choice in this setting [34], but other
agents that have a lower propensity to cause DIP
(as well as akathisia) include iloperidone and
clozapine [35, 36]. When antipsychotic switch-
ing is not a viable management strategy, addi-
tional strategies include: (1) gradually lowering
the antipsychotic dose if clinically possible, (2)
adding an anticholinergic medication, such as
benztropine or trihexyphenidyl, or (3) adding a
non-anticholinergic agent such as amantadine.
The use of potent dopaminergic medications
such as levodopa can exacerbate psychotic
symptoms [7].
Box 1 Summary of the basal ganglia direct and indirect pathways [74]
• The processing of movement in the basal ganglia involves a direct pathway and an indirect pathway
• The two pathways originate from distinct populations of striatal medium spiny neurons (MSNs) and project to different
output structures
• These circuits are believed to have opposite effects on movement: direct pathway MSNs promote movement but
activation of indirect pathway MSNs inhibit movement
Direct pathway Indirect pathway
Effect on motor thalamus Disinhibits Inhibits
Effect on thalamo-cortex Activates Inhibits
Effect on motor cortex Activates Inhibits
Effect on movement Facilitates Inhibits
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Anticholinergic medications, such as ben-
ztropine, are used extensively, and often pro-
phylactically, upon the initiation of antipsychotic
medication to manage DIP. However, these
medications can increase the risk of developing
TD, can worsen comorbid TD, and negatively
impact cognition [37]. The deleterious impact of
benztropine (and other anticholinergic medica-
tion) on memory is not trivial, and can be an
iatrogenic factor in the poor cognitive and func-
tional outcomes commonly encountered in per-
sons with schizophrenia [37]. Anticholinergic
medication should be avoided in the elderly
unless necessary due to an increased risk of
delirium [7], especially if already receiving medi-
cations with the potential for anticholinergic-in-
duced adverse effects. In addition to altered
mentation, peripheral side effects such as blurred
vision, dry mouth, constipation, and urinary
retention can be encountered. If prescribed, a
typical duration of anticholinergic use is
3 months, and they should be periodically stop-
ped to assess the need for continued use [11]. An
alternative to anticholinergic medications is
amantadine. Amantadine works to improve DIP
(and TD, discussed below) through unknown
mechanisms that may involve dopamine and N-
methyl-D-aspartate (NMDA) receptor antagonism
[38]. It may be a more viable option than anti-
cholinergic medications, particularly for elderly
patients, due to its reduced propensity for side
effects, but having similar efficacy as anticholin-
ergic medications when managing DIP [39]. A
study of 44 patients with schizophrenia who were
randomized to benztropine or amantadine were
found to experience similar improvement in
symptoms with less frequent side effects in the
amantadine group [39]. Another small (n = 41),
blinded, cross-over study comparing amantadine
to trihexyphenidyl in the treatment of neurolep-
tic-induced parkinsonism found similar results
[40]. The most common side effects in clinical
trials were insomnia, nausea, and dizziness
(5–10%), with anticholinergic-like side effects
among adverse events noted in 1–5% (anorexia,
dry mouth, constipation) [38]. Amantadine is not
expected to worsen TD symptoms and there is
modest evidence to suggest that it may reduce
dyskinetic movements (see below). Extended-re-
lease preparations of amantadine have recently
become available ‘‘for the treatment of dyskinesia
in patients with Parkinson’s disease receiving
levodopa-based therapy, with or without con-
comitant dopaminergic medications’’ [41] and for
‘‘Parkinson’s disease and drug-induced extrapyra-
midal reactions in adult patients’’ [42]. As with all
amantadine-containing products, risk of exacer-




Similar to DIP, published TD prevalence and
incidence rates may be falsely low [43]. In con-
trast to DIP, this is likely not due to confusion
with an idiopathic disorder as much as to a
decreased ability of providers to recognize the
insidious development of TD [44]. However, it
does appear that TD prevalence and incidence
estimates vary with past antipsychotic expo-
sure, antipsychotic class, and age. For example,
a large meta-analysis conducted by Carbon et al.
found that, in middle-aged patients, most of
whom had a schizophrenia-spectrum disorder,
the mean prevalence of TD among atypical
antipsychotic users was approximately 21%,
compared to 30% among current typical
antipsychotic users [45]. However, more long-
term studies that exclude patients with past
typical antipsychotic use will be necessary to
develop a clearer picture of the impact of atyp-
ical antipsychotics on TD risk [43]. On a cau-
tionary note, in a real-world prospective study,
the adjusted TD incidence rate-ratio for subjects
treated with atypical antipsychotics alone ver-
sus typical antipsychotics alone was 0.68 [46].
This suggests a small advantage for the newer
agents, but the 95% confidence interval of
0.29–1.64 implies that there may be no differ-
ence [46]. Alarmingly, the severity of the TD
was only slightly lower among incident cases of
TD appearing after recent atypical antipsychotic
exposure versus recent typical antipsychotic
exposure.
The rates of TD increase with duration of
therapy, as in younger adults taking typical
antipsychotics, reported rates of TD were
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approximately 4–5% annually, but this effect is
magnified by age [47]. For example, a longitu-
dinal study of TD in elderly patients noted that
31% (95% CI 20–42) of patients developed TD
after 43 weeks [48]. Prevalence rates become
more complex when looking at symptom per-
sistence in individuals diagnosed with TD. In
patients taking typical antipsychotics, although
about 50% appear to have TD symptoms that
stagnate, 10–30% will experience remission or
improvement of symptoms, and another
10–30% may have a worsening of symptoms
[49].
Pathophysiology
Disruptions in a number of neurotransmitter
systems and oxidative damage have been pro-
posed as potential pathways underlying TD.
These include dopamine receptor hypersensi-
tivity, altered amino acid metabolism and
GABA-containing neuron activity, and NMDA
receptor excitotoxicity [50]. Similar to DIP,
there is also evidence that genetics are associ-
ated with TD susceptibility [51]. Dopamine
receptor hypersensitivity is generally accepted
as playing a role in TD (Fig. 2) based on several
clinical observations, including temporary
improvement in symptoms with increased
antipsychotic dose or potency, and symptom
improvement in some patients when adminis-
tered VMAT2 inhibitors, such as tetrabenazine,
which decrease the amount of dopamine that is
ultimately released into the synapse.
Presentation and Diagnosis
TD is a subset of tardive syndromes associated
with antipsychotic drug use and is characterized
by involuntary, repetitive movements of the
face that includes lip smacking or puckering,
chewing, or tongue protrusion, but may also
result in uncontrolled movements in the
extremities, like contraction or writhing [50].
TD can worsen with stress. In contrast to DIP,
the abnormal movements observed with TD are
typically arrhythmic. Further information
regarding the term tardive syndromes and rela-
ted issues can be found elsewhere [52].
The Abnormal Involuntary Movement Scale
(AIMS) is used clinically and in research to
assess the abnormal movements associated with
TD [53]. Measuring the AIMS dyskinesia items
alone is inadequate, and questions regarding
functional impairments attributable to TD need
to be asked (e.g., interference with activities
such as eating, drinking, speaking, breathing,
dressing oneself, writing, working, leisure
activities, being with others) [54].
The Schooler–Kane research criteria are
commonly used to identify probable antipsy-
chotic-induced TD, and require that three
criteria are met: (1) symptoms occur after at
least 3 months of treatment with an antipsy-
chotic, (2) abnormal, involuntary movements
must occur in 2 or more body regions if mild,
or 1 body region if moderate to severe, as
determined by a rating scale such as the AIMS,
and (3) there are no other conditions that may
be causing the abnormal movement patterns
[55].
Risk Factors
Risk factors for TD are similar to those for
DIP, and primarily include older age and
increased antipsychotic medication exposure
(particularly typical antipsychotics), but also
to some degree female sex, African American
ethnicity, preexisting mood disorder, cogni-
tive disturbance, alcohol or substance abuse,
use of lithium or antiparkinsonian agents,
early occurrence of DIP, diabetes, and HIV
[56–58].
Management
The APA recommends monitoring patients with
schizophrenia for the development of TD every
3–12 months, depending on the patient’s risk
factors and the type of antipsychotic prescribed
[18]. Standards include every 6 months for
patients on a typical antipsychotic to every
12 months for patients on an atypical antipsy-
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chotic, and to monitor twice as frequently for
elderly patients and those with early, involun-
tary, movement patterns after starting an
antipsychotic [18]. These guidelines are likely
reasonable for most patients being treated with
antipsychotics, regardless of diagnosis.
Once TD is diagnosed and treatment is ini-
tiated, a baseline assessment should be
obtained, and the AIMS examination is recom-
mended for this purpose [54]. Advantages of
using the AIMS include its ubiquity both in the
clinic and in drug development, and that it can
Fig. 2 Hypothesized pathophysiology of tardive dyskinesia and the potential for vesicular monoamine transporter type 2
inhibition to treat the condition (reproduced with permission from [75])
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facilitate communication among providers.
Follow-up assessments to assess the effective-
ness of the intervention(s) should be carried out
on a regular basis.
One of the first steps in the management of
TD should be to gradually discontinue any
anticholinergic medications, as they may wor-
sen current symptoms [7]. In fact, symptoms
have been noted to improve in up to 60% of
people with TD after discontinuing an anti-
cholinergic [49, 59]. Unlike DIP, discontinuing
an antipsychotic or switching from a typical to
an atypical antipsychotic does not produce clear
evidence of benefit in patients requiring
antipsychotic use [60]. However, switching
antipsychotics, including a switch to clozapine,
is generally supported by older treatment algo-
rithms [61]. A recent review updating
the American Academy of Neurology (AAN) TD
treatment guidelines ranks treatment options
based on available evidence from A to C, where
A corresponds to established efficacy, B corre-
sponds to probable efficacy, and C corresponds
to potential efficacy [60]. Level A evidence for
efficacy exists for the two VMAT2 inhibitors,
valbenazine and deutetrabenazine, both re-
cently approved for the treatment of TD by the
United States Food and Drug Administration
(FDA), with a hypothesized mechanism of
action related to dopamine D2 receptor hyper-
sensitivity in the presence of chronic dopamine
D2 receptor blockade (Fig. 2).
Valbenazine was the first medication to
be approved for TD in the United States, and
improves upon tetrabenazine by having a more
tolerable side effect profile, potentially through
less off-site binding to dopaminergic, seroton-
ergic, adrenergic, histaminergic, and muscarinic
receptors, in addition to a more convenient
once-daily dosing regimen [62]. In a Phase III,
double-blind, randomized, 6-week, placebo-
controlled study of 234 participants random-
ized 1:1:1 to placebo or valbenazine 40 or
80 mg/day, daily doses of 80 mg were shown to
reduce AIMS total dyskinesia scores by - 3.2
points (P\0.001 when compared to
the placebo change score of - 0.1 points) and
by - 1.9 points in the 40 mg daily group
(P = 0.002 when compared to placebo) after
6 weeks of therapy [63]. The most common side
effects in the valbenazine group were somno-
lence (5%), akathisia (3%), and dry mouth (3%),
and discontinuation rates due to adverse events
were 4% in the valbenazine group versus 3% in
the placebo group [63]. A 1-year extension of
this study, which included 198 participants,
demonstrated continued efficacy and tolerabil-
ity, with the most common side effects being
headache (7%) and urinary retention (7%), with
16% discontinuing treatment due to an adverse
drug event [64].
Although the target dose for valbenazine is
80 mg/day (achieved after 1 week at
40 mg/day), 40 mg daily should not be excee-
ded in those with moderate to severe hepatic
impairment, or with concomitant use of strong
CYP3A4 inhibitors [62]. This is because valbe-
nazine is primarily metabolized by CYP3A4 to
inactive metabolites, although CYP2D6 also
plays a role in its metabolism [62]. In the case of
strong CYP2D6 inhibitors, or known CYP2D6
poor metabolizers, it is recommended to con-
sider reducing the dose based on tolerability
[62]. Valbenazine does not appear to impact the
common CYP isoenzymes itself, but does inhi-
bit P-glycoprotein, so digoxin should be moni-
tored carefully in patients requiring both
medications [62].
Valbenazine may prolong the electrocardio-
graphic QT interval, but the degree of QT pro-
longation is not clinically significant at
concentrations expected with recommended
dosing; nonetheless, valbenazine should be
avoided in patients with congenital long QT
syndrome or with arrhythmias associated with a
prolonged QT interval. For patients at increased
risk of a prolonged QT interval, it is suggested
that the QT interval be assessed before increas-
ing the dosage (i.e., from 40 to 80 mg/day) [62].
Deutetrabenazine was the second VMAT2
inhibitor approved by the FDA for the treat-
ment of TD. Deutetrabenazine is a deuterated
formulation of tetrabenazine; deuterium atoms
are substituted for hydrogen atoms at key loca-
tions in the molecule, altering its pharmacoki-
netics because deuterium–carbon chemical
bonds are many-fold stronger than hydro-
gen–carbon bonds. Deuterium is naturally
occurring ‘‘heavy hydrogen’’ and is not
radioactive. Compared to tetrabenazine,
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metabolism is slowed, reducing the number of
doses required per day, decreasing plasma level
variability, and improving tolerability [30].
Recommended dosing for deutetrabenazine is
twice daily with food, starting at 6 mg twice
daily and increasing by 6 mg weekly up to a
maximum dose of 24 mg twice daily, based on
tolerability and reduction of TD [30]. In a Phase
II, 12-week, clinical trial (n = 117) which
allowed titration to optimal efficacy and toler-
ability, the mean dose achieved was
38.8 mg/day [65]. A Phase III, double-blind,
12-week, placebo-controlled, randomized trial
was conducted to compare deutetrabenazine at
doses of 12, 24, and 36 mg/day to placebo in
298 patients [66]. The randomization
scheme was 1:1:1:1 and the deutetrabenazine
dose was increased over 4 weeks. The primary
end-point measure was change in AIMS scores
from baseline to week 12. At week 12, the
treatment difference from baseline (SE) was
- 1.4 in the placebo group and - 2.1 (P = 0.217
when compared with placebo), - 3.2
(P = 0.003) and - 3.3 (P = 0.001) for the 12-,
24-, and 36-mg/day treatment groups, respec-
tively [66]. The most common side effects in the
deutetrabenazine groups were headache (5%),
anxiety (4%), and diarrhea (4%), and discon-
tinuation due to side effects occurred in 4% of
the treatment group and 3% of the placebo
group [66]. Deutetrabenazine metabolism
involves CYP2D6; in the presence of CYP2D6
inhibitors or in patients who are known poor
CYP2D6 metabolizers, the total daily dosage of
deutetrabenazine should not exceed 36 mg [30].
Deutetrabenazine may prolong the QT interval
and use should be avoided in patients with
congenital long QT syndrome or with arrhyth-
mias associated with a prolonged QT interval.
For patients at increased risk of a prolonged QT
interval, it is suggested that the QT interval be
Table 1 Differentiating characteristics of drug-induced parkinsonism (DIP) versus tardive dyskinesia (TD)
Characteristic DIP TD
Onset Immediate (hours–days–weeks) after
initiation of an antipsychotic or after
dose is increased
Delayed (months–years) after initiation of an
antipsychotic
Motor symptoms observed Rhythmic tremor, rigidity, shuffling gait;
akathisia may be present
Arrhythmic movements (generally choreo-






















VMAT2 vesicular monoamine transporter 2
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Table 2 A comparison of the key characteristics and recommended dosing considerations for valbenazine and deutetra-
benazine use in the management of TD. Adapted from [30, 62, 75]
Valbenazine Deutetrabenazine
Brand name Ingrezza Austedo
Available dose formulation Capsules: 40 and 80 mg Tablets: 6, 9, and 12 mg
Other indications None Chorea associated with Huntington’s disease
Active metabolites [?]-a-HTBZ Deuterated a-HTBZ and b-HTBZ




None Hepatic impairment, use of reserpine,
MAOIs, tetrabenazine or valbenazine
Warnings and precaution
contained in Highlights of
Prescribing Information
Somnolence; QT interval prolongation QT interval prolongation; neuroleptic
malignant syndrome; akathisia, agitation,
restlessness, and parkinsonism (latter not
applicable to TD); sedation/somnolence
Dosing frequency Once daily Twice daily
Recommended dosing Take with or without food; start at 40 mg
daily, increase to 80 mg daily after 1 week
Take with food; start at 12 mg/day, increase
by 6 mg/day at weekly intervals up to
48 mg/day, based on tolerability and
response
CYP2D6 poor metabolizers Base dose on tolerability Maximum recommended dose is 36 mg/day
Hepatic impairment Moderate-to-severe hepatic impairment:
maximum recommended dose is
40 mg/day
Contraindicated
Renal impairment Avoid in severe renal impairment; no dosing
changes are recommended for mild-to-
moderate impairment
Package insert does not provide any
recommendations (cites a lack of studies in
this population), but the metabolites are
excreted renally
Drug-drug interactions Valbenazine increases digoxin levels; consider
valbenazine dose reduction with strong
CYP2D6 inhibitors; with strong CYP3A4
inhibitors the maximum recommended
dose is 40 mg daily; use is not
recommended with MAOIs or CYP3A4
inducers
Additive sedation may occur with alcohol
and other CNS depressants; with strong
CYP2D6 inhibitors, the recommended
maximum dose is 36 mg/day
QT prolongation
recommendation
If the patient is at increased risk for QT
prolongation, assess QT interval before
increasing the dose
If the patient is at increased risk for QT
prolongation, assess QT interval before and
after increasing the dose above 24 mg/day
HTBZ dihydrotetrabenazine, TD tardive dyskinesia, MAOIs monoamine oxidase inhibitors, CNS central nervous system
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assessed before and after increasing the total
dose above 12 mg BID [30].
Unlike valbenazine, deutetrabenazine is also
approved for the treatment of Huntington’s
disease, and contains language in its product
label that is specific to tolerability concerns for
that population and differs from that for TD (for
example, there is a boxed warning for depres-
sion and suicidality that has been observed in
patients with Huntington’s disease). Other dif-
ferences between valbenazine and deutetra-
benazine are summarized in Table 2.
Additional medication interventions for TD
are not FDA-approved and carry lower levels of
evidence compared to valbenazine and
deutetrabenazine in the AAN guidelines. Level B
AAN recommendations for the treatment of TD
include Ginkgo biloba and clonazepam. Level C
options that might be considered include
amantadine, tetrabenazine, and pallidal deep
brain stimulation [60]. Amantadine is unique
among medications used to treat DIP and TD, in
the respect that it has evidence supporting its use
for both indications. However, the therapeutic
effect for TD is modest. When compared to pla-
cebo, amantadine has been shown to decrease
AIMS scores by approximately 15–22% in small,
relatively short-term, placebo-controlled, cross-
over studies [67, 68]. Drowsiness, fatigue,
insomnia, constipation, and dizziness occurred
more frequently with amantadine than placebo
in these studies [67, 68]. Tetrabenazine is used
off-label for the treatment of TD in the United
States; however, in other jurisdictions, such as
the UK, Canada, New Zealand, Australia, Ger-
many, Italy, Israel, France, and Portugal, it is
approved for this purpose [69]. Two small, clin-
ical trials were cited in the AAN recommenda-
tion supporting the use of tetrabenazine for the
treatment of TD symptoms, as supported by
significant reductions in AIMS scores [70, 71].
Although tolerability was not a major issue in
these studies, clinical experience with side effects
of tetrabenazine that occur in more than 5% of
patients in persons with Huntington’s disease
(such as sedation, insomnia, depression, akathi-
sia, parkinsonism, instability, irritability) [72],
and the requirement to dose the medication up
to 3 times per day, and assessing for CYP 2D6
poor/extensive metabolizers if doses greater than
50 mg/day need to be used, led to the develop-
ment of the two tetrabenazine alternatives, val-
benazine and deutetrabenazine, discussed
previously.
Co-occurrence of DIP and TD
It is possible for patients treated with antipsy-
chotics to have both DIP and TD, with DIP pre-
sumably preceding TD. Although the
mechanism is not fully understood, observations
regarding the differences in neural pathways
between DIP and comorbid DIP and TD are pre-
sented in Fig. 1 [2, 10, 73]. As compared to
Fig. 1a, Fig. 1b details relatively greater excitatory
signaling between the thalamus and the cerebral
cortex, potentially explaining TD symptoms
occurring in the setting of DIP. For patients
experiencing both disorders, treatment options
include amantadine (with or without a VMAT2
inhibitor), which may have some positive
impact on both disorders. Anticholinergic med-
ication should be avoided or minimized in order
to lessen potential adverse impact on TD symp-
toms. Randomized controlled trials of VMAT2
inhibitors in persons with co-occurring DIP and
TD will help answer the question of whether or
not the decrease in dopamine release observed
with VMAT2 inhibition would have significant
clinical impact on the severity of the DIP.
CONCLUSION
DIP and TD are potential adverse events of
antipsychotics that occur at significant rates
with both typical and atypical antipsychotic
use. DIP can be difficult to recognize and diag-
nose, especially in the elderly, due to its simi-
larity to Parkinson’s disease, but most often
presents within the first 3 months of therapy
[27]. TD, however, typically does not develop
until after 3 months or longer of antipsychotic
drug use (although there may be the occasional
exception). Among the agents used to treat DIP,
amantadine is expected to be better tolerated
than anticholinergics, particularly in the
elderly. Valbenazine and deutetrabenazine are
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